查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1324296

到 2030 年病毒疫苗市场预测 - 按类型、型态、容器形状、生物安全级别类型、技术、疾病、给药年龄、给药途径、最终用户和地区进行的全球分析

Viral Vaccines Market Forecasts to 2030 - Global Analysis By Type, Form, Container Format, Biosafety Level Type, Technology, Disease, Age of Administration, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC的数据，2023年全球病毒疫苗市场规模为1005.7亿美元，预计到2030年将达到1482.5亿美元，预测期内年复合成长率为5.7%。

病毒疫苗被认为是预防病毒病原体引起的病毒感染疾病的最有效手段之一。除了人类免疫缺陷病毒（HIV/AIDS）、埃博拉病毒、流感、COVID-19 和许多其他严重的病毒感染疾病之外，病毒还引起许多众所周知的感染疾病，包括普通感冒、流感和疣。世界范围内各种病毒感染疾病的流行情况因地区、季节甚至一周中的不同日期而异。因此，对这些药物的需求也发生了变化。

据世界卫生组织称，病毒性肝炎罹患3.25 亿人，约占世界人口的 4%，每年导致 134 万人死亡。

促进因素：感染疾病的蔓延和死灰復燃

生活在人口稠密的地区，旅行更加频繁，距离更长，人类与野生动物之间的接触不断增加，意味着新的感染疾病可以迅速传播并在世界范围内引起大流行，引起严重关注。此外，出于恐怖主义目的而故意将人、动物或植物引入社区，也可能导致疾病传播。已发现约 40 种感染疾病，包括 SARS、MERS、埃博拉、基孔肯雅热、禽流感、猪流感、寨卡病毒和最近的 COVID-19。专家警告说，未来的大流行和流行病将比 COVID-19 致命得多。

疫苗研发成本高

疫苗研发需要大量资金。疫苗需要特殊的设备和监控系统来储存和运输，这使得它们比其他药品更昂贵。储存和运输基础设施不足可能会影响疫苗的功效和质量。从体外研究到商业化，开发过程需要10至15年，成本在8亿美元至10亿美元之间。此外，疫苗研究的成功率较低，导致公司难以管理运营费用和确保初始投资。因此，疫苗生产和储存成本高昂，阻碍了市场扩张。

新兴市场强劲的增长预测

中国、印度和东南亚等新兴地区由于患者人数和可支配收入的增加，疫苗行业具有扩张潜力。大型市场公司被这些新兴经济体的市场开拓潜力所吸引并进行投资。开发负担得起且易于获得的免疫接种也是公司投资并重点扩大这些经济体免疫计划覆盖范围的一个领域。

获得疫苗的机会不公平

疫苗获取不公平对病毒疫苗市场构成重大威胁。疫苗的全球分发和供应对于对抗感染疾病和确保公共卫生至关重要。然而，获得疫苗的机会在不同国家和人群中分布不均，这阻碍了疫苗接种的有效性，并使某些地区容易爆发疫情。此外，不平等的准入可能由多种要素引起，包括经济差异、地缘政治课题、供应链限制和知识产权。虽然高所得国家往往能够更好地获得疫苗，但低收入国家却难以确保足够的供应。这种差异不仅导致医疗保健结果的差异，而且破坏了全球控制和消除病毒性疾病的努力。

COVID-19 的影响

由于疫苗接种率和接种疫苗总数下降，COVID-19 大流行影响了世界各地卫生服务的提供，特别是免疫计划。结果，儿童无法接种疫苗，疫苗市场萎缩。在全球范围内，各国政府都试图遏制病毒的传播，包括大规模封锁、关闭边境和禁止大型集会。这些措施推迟了许多倡议的实施，包括疫苗接种活动。此外，为了减少 COVID-19 的影响，世卫组织已发布指导方针，暂停世界各地的大规模免疫规划活动。

预计小瓶细分市场在预测期内将是最大的细分市场

西林瓶细分市场的需求正在增加，因为它比预充式註射器更具成本效益，并且占据了市场上最大的份额。这些小玻璃或塑料容器提供无菌环境，以保持疫苗配方的效力和完整性。病毒疫苗市场使用的小瓶的设计符合严格的质量标准，确保疫苗的安全性和有效性。然而，这些小瓶是根据其与疫苗成分的相容性、抗破损性以及随着时间的推移保持产品稳定性的能力而专门选择的。通常用橡胶塞或铝盖密封，以防止污染并保持无菌环境。

在预测期内，冻干产品领域预计年复合成长率最高

预计冷冻干燥领域在预测期内的年复合成长率最高。冷冻干燥通过低温和减压下的昇华从疫苗配方中去除水分。因此，冻干病毒疫苗是固体和干燥的，在稳定性、储存和运输方面具有多种优势。此外，冷冻干燥可以通过减少变质和保持效力来帮助延长病毒疫苗的保质期。通过去除可能引起化学和生物反应的水分，冻干疫苗更加稳定，可以保存更长时间，无需冷藏。

占比最大的地区：

据估计，在预测期内，亚太地区将占据全球病毒疫苗市场的最高份额。这是人口膨胀、中产阶级可支配收入增加、工业化和都市化快速发展等因素造成的。该地区小型和大型製造商的存在也支持了农用轮胎行业的扩张。斜交农用轮胎采用製造技术和材料生产，能够以合理的价格提供卓越的负担能力。天然橡胶是製造斜交轮胎所需的主要原材料。因此，亚太地区泰国、印度、越南、印尼、中国、马来西亚等国家的天然橡胶供应充足，预计将增加该地区的市场需求。

复合年复合成长率最高的地区：

预计北美地区在预测期内将呈现最高增长率。这一增长归因于生活水准提高、外国投资和消费增加对农产品的高需求。此外，美国和加拿大等国家的农业增长也导致病毒疫苗的需求增加。与此同时，农业机械化程度也在不断提高，这也带动了北美地区的市场增长。

免费定制服务：

订阅此报告的客户将收到以下免费定制选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（注：基于可行性检查）
  • 竞争标杆管理
    • 根据产品系列、地域分布和战略联盟对主要企业进行基准测试

目录

第1章执行摘要

第2章前言

  • 概述
  • 利益相关者
  • 调查范围
  • 调查方法
    • 资料挖掘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 假设

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球病毒疫苗市场：按类型

  • 单价疫苗
  • 多价疫苗

第6章全球病毒疫苗市场：按型态

  • 液体
  • 冷冻干燥

第7章全球病毒疫苗市场：按容器形状

  • 小瓶
  • 预充式註射器

第8章全球病毒疫苗市场：按生物安全级别类型

  • 生物安全1级
  • 生物安全2级
  • 生物安全3级
  • 生物安全4级

第9章全球病毒疫苗市场：按技术分类

  • 不包括 COVID-19感染疾病
    • 结合疫苗
    • 灭活疫苗和亚单位疫苗
    • 减毒活疫苗
    • 重组疫苗
    • 类毒素疫苗
    • 病毒载体疫苗
  • 包括 COVID-19感染疾病
    • 信使核糖核酸 (mRNA) 疫苗
    • 病毒载体疫苗
  • 其他的

第10章全球病毒疫苗市场：按疾病分类

  • 流感
  • 肺炎球菌疾病
  • 联合疫苗
  • 人乳头瘤病毒 (HPV)
  • 带状疱疹
  • 脑膜炎球菌病
  • 轮状病毒
  • 麻疹、腮腺炎、德国麻疹(MMR)
  • 水痘
  • 肝炎
  • 白喉、破伤风、百日咳 (DTP)
  • 脊髓灰质炎
  • COVID-19
  • 其他的

第11章全球病毒疫苗市场：按给药年龄分类

  • 儿科疫苗
  • 成人疫苗

第12章全球病毒疫苗市场：按给药途径分类

  • 肌内和皮下给药
  • 口服给药
  • 其他的

第13章全球病毒疫苗市场：按最终用户分类

  • 地区医院
  • 医院
  • 专业中心
  • 诊所
  • 其他的

第14章全球病毒疫苗市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第15章进展

  • 合同、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第16章公司简介

  • AstraZeneca plc
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis, Inc.
  • Novavax, Inc.
  • Pfizer, Inc.
  • Sanofi
  • Seqirus（CSL Limited）
  • Serum institute of India Private Limited
Product Code: SMRC23521

According to Stratistics MRC, the Global Viral Vaccines Market is accounted for $100.57 billion in 2023 and is expected to reach $148.25 billion by 2030 growing at a CAGR of 5.7% during the forecast period. Viral vaccines are considered one of the most effective prevention measures against viral infections caused by viral agents. Along with other serious viral infections including the human immunodeficiency virus (HIV/AIDS), Ebola, influenza, COVID-19, and many others, viruses also cause a number of well-known infectious diseases, including the common cold, flu, and warts. The prevalence of various viral infections varies globally by region, season, and even day of the week. As a result, there is a variable need for these medications.

According to WHO, 325 million people, or roughly 4% of the world's population, live with viral hepatitis and the disease causes 1.34 million deaths per year

Market Dynamics:

Driver:

Infectious diseases are growing more widespread and were re-emerging

Living in more densely populated places, traveling much more frequently and over longer distances than in the past, and increasing human-wildlife contact raise serious concerns about the potential for new infectious diseases to spread quickly and trigger pandemics over the world. Additionally, there's a chance that diseases could spread as a result of intentional introduction into communities of people, animals, or plants for terrorist goals. About 40 infectious diseases, including SARS, MERS, Ebola, chikungunya, avian flu, swine flu, Zika, and most recently COVID-19, have been identified. Future pandemics and epidemics will be much deadlier than COVID-19, experts have warned.

Restraint:

High cost of vaccine development

The process of developing vaccines requires a significant amount of capital. The cost of storing and shipping vaccinations is higher than that of any other pharmaceutical product because they need specific facilities and monitoring systems. The effectiveness and quality of vaccines can suffer from inadequate storage and delivery infrastructure. From in vitro research to marketing, the development process takes 10 to 15 years and costs between US$800 million and US$1 billion. Additionally, because vaccine research has a poor success rate, businesses struggle to control operational expenses and secure initial investments. Therefore, the high cost of vaccine production and storage is limiting market expansion.

Opportunity:

High growth prospects in emerging markets

Due to the rising patient populations and disposable incomes, emerging regions like China, India, and Southeast Asia present expanding potential for the vaccination industry. Major market firms have been enticed to invest in these economies by their development potential. The development of low-cost, accessible vaccinations is another area in which businesses are investing and concentrating in order to expand the reach of immunization programs in these economies.

Threat:

Inequitable access to vaccines

Inequitable access to vaccines poses a significant threat to the viral vaccines market. The global distribution and availability of vaccines are crucial for combating infectious diseases and ensuring public health. However, when access to vaccines is unevenly distributed across countries and populations, it hinders the effectiveness of vaccination efforts and leaves certain regions vulnerable to outbreaks. Additionally, inequitable access can arise from various factors, including economic disparities, geopolitical challenges, supply chain limitations, and intellectual property rights. High-income countries often have better access to vaccines, while lower-income countries struggle to secure an adequate supply. This imbalance not only leads to disparities in healthcare outcomes but also undermines global efforts to control and eradicate viral diseases.

COVID-19 Impact:

The COVID-19 pandemic had an impact on the delivery of health services, particularly immunization programs, all over the world as a fall in vaccination coverage and the overall number of vaccines given was noted. Children missed out on their vaccine doses as a result of this reduction, which reduced the market for these items. Globally, governments made efforts to control the spread by imposing population-wide lockdowns, closing borders, and prohibiting large gatherings. These actions slowed the implementation of numerous initiatives, including vaccine campaigns. Additionally, in order to lessen the effects of COVID-19, the WHO published guidelines for temporarily suspending the activities of mass vaccination programs around the world.

The vials segment is expected to be the largest during the forecast period

The vials segment held the largest share in the market owing to the increasing demand due to its cost effectiveness over prefilled syringes. These small glass or plastic containers provide a sterile environment to preserve the potency and integrity of the vaccine formulations. Vials used in the viral vaccines market are designed to meet stringent quality standards, ensuring the safety and efficacy of the vaccines. However, Vials are specifically chosen for their compatibility with vaccine ingredients, resistance to breakage, and ability to maintain product stability over time. They are typically sealed with rubber stoppers and aluminum caps to prevent contamination and maintain a sterile environment.

The lyophilized segment is expected to have the highest CAGR during the forecast period

During the projection period, the lyophilized segment is expected to have the greatest CAGR. It involves the removal of water from a vaccine formulation through sublimation under low temperature and reduced pressure. The resulting lyophilized viral vaccines are in a solid, dry state, offering several advantages in terms of stability, storage, and transportation. Additionally, lyophilisation helps to extend the shelf life of viral vaccines by reducing degradation and preserving their potency. By removing water, which can contribute to chemical and biological reactions, the lyophilized vaccines exhibit enhanced stability, allowing for longer-term storage without the need for refrigeration.

Region with largest share:

The Asia Pacific region market is estimated to witness the highest share of the global Viral Vaccines market during the forecast period. This is ascribed to elements including the expanding population, rising middle-class discretionary income, and the quick industrialization and urbanization. The expansion of the farm tire sector may also be aided by the region's presence of both small and large-scale manufacturers. Bias farm tires are produced using manufacturing techniques and materials that provide good load capabilities at reasonable prices. Natural rubber is the primary raw material needed to make bias tires. As a result, it is anticipated that the Asia Pacific region's plentiful supply of natural rubber in countries like Thailand, India, Vietnam, Indonesia, China, and Malaysia will increase demand of the market in the region.

Region with highest CAGR:

The North America region is expected to have the highest growth rate over the forecast period. This growth can be attributed high demand for agricultural goods owing to rising living standards, foreign investments and increased consumption. Moreover, growing agricultural industry of countries such as the U.S. and Canada in the region is leading to growing demand for viral vaccines. Along with this, the mechanization in agriculture is also growing in the region, which is also driving the market growth of the North America region.

Key players in the market:

Some of the key players in Viral Vaccines market include: AstraZeneca plc, Emergent BioSolutions Inc., GlaxoSmithKline plc, Merck & Co., Inc., Moderna, Inc., Novartis, Inc., Novavax, Inc., Pfizer, Inc., Sanofi, Seqirus (CSL Limited) and Serum institute of India Private Limited.

Key Developments:

In November 2022, The U.S. FDA granted a Priority Review for GSK's Respiratory Syncytial Virus (RSV) older adult vaccine candidate

In July 2022, CSL SEQIRUS entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute to advance influenza protection and pandemic preparedness

In June 2022, Bavarian Nordic A/S entered into a five-year contract with the government of Canada to procure the IMVAMUNE smallpox vaccine

In July 2021, GSK received US FDA approval for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy

In June 2021, Merck announced the launch of VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) in the US, developed in partnership with Sanofi Pasteur

Types Covered:

  • Monovalent Vaccines
  • Multivalent Vaccines

Forms Covered:

  • Liquid
  • Lyophilized

Container Formats Covered:

  • Vials
  • Prefilled Syringes

Biosafety Level Types Covered:

  • Biosafety Level 1
  • Biosafety Level 2
  • Biosafety Level 3
  • Biosafety Level 4

Technologies Covered:

  • Excluding COVID 19 Vaccines
  • Including COVID 19 Vaccine
  • Other Technologies

Diseases Covered:

  • Influenza
  • Pneumococcal Diseases
  • Combination Vaccines
  • Human Papillomavirus (HPV)
  • Herpes Zoster
  • Meningococcal Diseases
  • Rotavirus
  • Measles, Mumps, Rubella (MMR)
  • Varicella
  • Hepatitis
  • Diphtheria, Tetanus And Pertussis (DTP)
  • Polio
  • COVID-19
  • Other Diseases

Age of Administrations Covered:

  • Pediatric Vaccine
  • Adult Vaccine

Route of Administrations Covered:

  • Intramuscular & Subcutaneous Administration
  • Oral Administration
  • Other Routes Of Administrations

End Users Covered:

  • Community Hospitals
  • Hospitals
  • Specialty Centres
  • Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viral Vaccines Market, By Type

  • 5.1 Introduction
  • 5.2 Monovalent Vaccines
  • 5.3 Multivalent Vaccines

6 Global Viral Vaccines Market, By Form

  • 6.1 Introduction
  • 6.2 Liquid
  • 6.3 Lyophilized

7 Global Viral Vaccines Market, By Container Format

  • 7.1 Introduction
  • 7.2 Vials
  • 7.3 Prefilled Syringes

8 Global Viral Vaccines Market, By Biosafety Level Type

  • 8.1 Introduction
  • 8.2 Biosafety Level 1
  • 8.3 Biosafety Level 2
  • 8.4 Biosafety Level 3
  • 8.5 Biosafety Level 4

9 Global Viral Vaccines Market, By Technology

  • 9.1 Introduction
  • 9.2 Excluding COVID 19 Vaccines
    • 9.2.1 Conjugate Vaccines
    • 9.2.2 Inactivated & Subunit Vaccines
    • 9.2.3 Live Attenuated Vaccines
    • 9.2.4 Recombinant Vaccines
    • 9.2.5 Toxoid Vaccines
    • 9.2.6 Viral vector Vaccines
  • 9.3 Including COVID 19 Vaccine
    • 9.3.1 Messenger Ribonucleic Acid (mRNA) Vaccines
    • 9.3.2 Viral Vector Vaccines
  • 9.4 Other Technologies

10 Global Viral Vaccines Market, By Disease

  • 10.1 Introduction
  • 10.2 Influenza
  • 10.3 Pneumococcal Diseases
  • 10.4 Combination Vaccines
  • 10.5 Human Papillomavirus (HPV)
  • 10.6 Herpes Zoster
  • 10.7 Meningococcal Diseases
  • 10.8 Rotavirus
  • 10.9 Measles, Mumps, Rubella (MMR)
  • 10.10 Varicella
  • 10.11 Hepatitis
  • 10.12 Diphtheria, Tetanus and Pertussis (DTP)
  • 10.13 Polio
  • 10.14 COVID 19
  • 10.15 Other Diseases

11 Global Viral Vaccines Market, By Age of Administration

  • 11.1 Introduction
  • 11.2 Pediatric Vaccine
  • 11.3 Adult Vaccine

12 Global Viral Vaccines Market, By Route of Administration

  • 12.1 Introduction
  • 12.2 Intramuscular & Subcutaneous Administration
  • 12.3 Oral Administration
  • 12.4 Other Routes Of Administrations

13 Global Viral Vaccines Market, By End User

  • 13.1 Introduction
  • 13.2 Community Hospitals
  • 13.3 Hospitals
  • 13.4 Specialty Centres
  • 13.5 Clinics
  • 13.6 Other End Users

14 Global Viral Vaccines Market, By Geography

  • 14.1 Introduction
  • 14.2 North America
    • 14.2.1 US
    • 14.2.2 Canada
    • 14.2.3 Mexico
  • 14.3 Europe
    • 14.3.1 Germany
    • 14.3.2 UK
    • 14.3.3 Italy
    • 14.3.4 France
    • 14.3.5 Spain
    • 14.3.6 Rest of Europe
  • 14.4 Asia Pacific
    • 14.4.1 Japan
    • 14.4.2 China
    • 14.4.3 India
    • 14.4.4 Australia
    • 14.4.5 New Zealand
    • 14.4.6 South Korea
    • 14.4.7 Rest of Asia Pacific
  • 14.5 South America
    • 14.5.1 Argentina
    • 14.5.2 Brazil
    • 14.5.3 Chile
    • 14.5.4 Rest of South America
  • 14.6 Middle East & Africa
    • 14.6.1 Saudi Arabia
    • 14.6.2 UAE
    • 14.6.3 Qatar
    • 14.6.4 South Africa
    • 14.6.5 Rest of Middle East & Africa

15 Key Developments

  • 15.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 15.2 Acquisitions & Mergers
  • 15.3 New Product Launch
  • 15.4 Expansions
  • 15.5 Other Key Strategies

16 Company Profiling

  • 16.1 AstraZeneca plc
  • 16.2 Emergent BioSolutions Inc.
  • 16.3 GlaxoSmithKline plc
  • 16.4 Merck & Co., Inc.
  • 16.5 Moderna, Inc.
  • 16.6 Novartis, Inc.
  • 16.7 Novavax, Inc.
  • 16.8 Pfizer, Inc.
  • 16.9 Sanofi
  • 16.10 Seqirus (CSL Limited)
  • 16.11 Serum institute of India Private Limited

List of Tables

  • Table 1 Global Viral Vaccines Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Viral Vaccines Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Viral Vaccines Market Outlook, By Monovalent Vaccines (2021-2030) ($MN)
  • Table 4 Global Viral Vaccines Market Outlook, By Multivalent Vaccines (2021-2030) ($MN)
  • Table 5 Global Viral Vaccines Market Outlook, By Form (2021-2030) ($MN)
  • Table 6 Global Viral Vaccines Market Outlook, By Liquid (2021-2030) ($MN)
  • Table 7 Global Viral Vaccines Market Outlook, By Lyophilized (2021-2030) ($MN)
  • Table 8 Global Viral Vaccines Market Outlook, By Container Format (2021-2030) ($MN)
  • Table 9 Global Viral Vaccines Market Outlook, By Vials (2021-2030) ($MN)
  • Table 10 Global Viral Vaccines Market Outlook, By Prefilled Syringes (2021-2030) ($MN)
  • Table 11 Global Viral Vaccines Market Outlook, By Biosafety Level Type (2021-2030) ($MN)
  • Table 12 Global Viral Vaccines Market Outlook, By Biosafety Level 1 (2021-2030) ($MN)
  • Table 13 Global Viral Vaccines Market Outlook, By Biosafety Level 2 (2021-2030) ($MN)
  • Table 14 Global Viral Vaccines Market Outlook, By Biosafety Level 3 (2021-2030) ($MN)
  • Table 15 Global Viral Vaccines Market Outlook, By Biosafety Level 4 (2021-2030) ($MN)
  • Table 16 Global Viral Vaccines Market Outlook, By Technology (2021-2030) ($MN)
  • Table 17 Global Viral Vaccines Market Outlook, By Excluding COVID 19 Vaccines (2021-2030) ($MN)
  • Table 18 Global Viral Vaccines Market Outlook, By Conjugate Vaccines (2021-2030) ($MN)
  • Table 19 Global Viral Vaccines Market Outlook, By Inactivated & Subunit Vaccines (2021-2030) ($MN)
  • Table 20 Global Viral Vaccines Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
  • Table 21 Global Viral Vaccines Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 22 Global Viral Vaccines Market Outlook, By Toxoid Vaccines (2021-2030) ($MN)
  • Table 23 Global Viral Vaccines Market Outlook, By Viral vector Vaccines (2021-2030) ($MN)
  • Table 24 Global Viral Vaccines Market Outlook, By Including COVID 19 Vaccine (2021-2030) ($MN)
  • Table 25 Global Viral Vaccines Market Outlook, By Messenger Ribonucleic Acid (mRNA) Vaccines (2021-2030) ($MN)
  • Table 26 Global Viral Vaccines Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 27 Global Viral Vaccines Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 28 Global Viral Vaccines Market Outlook, By Disease (2021-2030) ($MN)
  • Table 29 Global Viral Vaccines Market Outlook, By Influenza (2021-2030) ($MN)
  • Table 30 Global Viral Vaccines Market Outlook, By Pneumococcal Diseases (2021-2030) ($MN)
  • Table 31 Global Viral Vaccines Market Outlook, By Combination Vaccines (2021-2030) ($MN)
  • Table 32 Global Viral Vaccines Market Outlook, By Human Papillomavirus (HPV) (2021-2030) ($MN)
  • Table 33 Global Viral Vaccines Market Outlook, By Herpes Zoster (2021-2030) ($MN)
  • Table 34 Global Viral Vaccines Market Outlook, By Meningococcal Diseases (2021-2030) ($MN)
  • Table 35 Global Viral Vaccines Market Outlook, By Rotavirus (2021-2030) ($MN)
  • Table 36 Global Viral Vaccines Market Outlook, By Measles, Mumps, Rubella (MMR) (2021-2030) ($MN)
  • Table 37 Global Viral Vaccines Market Outlook, By Varicella (2021-2030) ($MN)
  • Table 38 Global Viral Vaccines Market Outlook, By Hepatitis (2021-2030) ($MN)
  • Table 39 Global Viral Vaccines Market Outlook, By Diphtheria, Tetanus and Pertussis (DTP) (2021-2030) ($MN)
  • Table 40 Global Viral Vaccines Market Outlook, By Polio (2021-2030) ($MN)
  • Table 41 Global Viral Vaccines Market Outlook, By COVID 19 (2021-2030) ($MN)
  • Table 42 Global Viral Vaccines Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 43 Global Viral Vaccines Market Outlook, By Age of Administration (2021-2030) ($MN)
  • Table 44 Global Viral Vaccines Market Outlook, By Pediatric Vaccine (2021-2030) ($MN)
  • Table 45 Global Viral Vaccines Market Outlook, By Adult Vaccine (2021-2030) ($MN)
  • Table 46 Global Viral Vaccines Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 47 Global Viral Vaccines Market Outlook, By Intramuscular & Subcutaneous Administration (2021-2030) ($MN)
  • Table 48 Global Viral Vaccines Market Outlook, By Oral Administration (2021-2030) ($MN)
  • Table 49 Global Viral Vaccines Market Outlook, By Other Routes Of Administrations (2021-2030) ($MN)
  • Table 50 Global Viral Vaccines Market Outlook, By End User (2021-2030) ($MN)
  • Table 51 Global Viral Vaccines Market Outlook, By Community Hospitals (2021-2030) ($MN)
  • Table 52 Global Viral Vaccines Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 53 Global Viral Vaccines Market Outlook, By Specialty Centres (2021-2030) ($MN)
  • Table 54 Global Viral Vaccines Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 55 Global Viral Vaccines Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.